Concerns over data manipulation lands Chinese API maker with US FDA Warning

By Dan Stanton contact

- Last updated on GMT

Yunnan Hande Bio-Tech makes the API for cancer-drug paclitaxel, derived from the bark of yew trees
Yunnan Hande Bio-Tech makes the API for cancer-drug paclitaxel, derived from the bark of yew trees

Related tags: Food and drug administration

The US FDA has hit cancer-drug API maker Yunnan Hande Bio-Tech with a warning letter citing concerns over potential manipulation of quality test data at a plant in China.

The plant in Kunming, Yunnan Province was inspected in April last year by the US Food and Drug Administration (FDA) and a warning letter​ identifying deviations from current good manufacturing practice (CGMP) was sent to the company earlier this month.

“You lacked controls to prevent the unauthorized manipulation of your laboratory's electronic raw data. Specifically, your infrared (IR) spectrometer did not have access controls to prevent deletion or alteration of raw data,”​ the agency said.

During the inspection the FDA noted a Hande Bio-Tech employee failed to perform the IR identity test for lots of a specific API as part of the quality control release.

“Instead, the analyst at your firm altered the file name in the spectrophotometer containing the sample identification information… tested on April 2, 2014, to support the release of two previously manufactured lots.”

The inspectors also noted the firm’s quality unit’s failure to exercise its responsibility to ensure the APIs are in compliance with CGMP, and meet established specifications for quality and purity.

The letter is the second the facility has received in recent years, with the FDA hitting the firm with a warning​ in 2010 after complaints surrounding certain API batches were not investigated properly.

Yunnan Hande Bio-Tech manufactures the ingredients for the drugs paclitaxel and cephalomannine, both of which are major taxanes produced by yew trees and used to treat a number of types of cancer including ovarian, breast, lung and pancreatic cancer.

The company did not respond to requests for more information when contacted by this publication.

Related news

Show more

Related products

How to resolve sticking issues in tablet production

How to resolve sticking issues in tablet production

I Holland Limited - Tabletting Science | 24-Jun-2019 | Case Study

Tablet sticking is one of the most common problems in tablet manufacture. Find out how I Holland used the TSAR scientific predictive model and expert tablet...

How to measure powder and granule flow properties

How to measure powder and granule flow properties

Stable Micro Systems | 01-Apr-2019 | Technical / White Paper

Being able to predict, optimise and control powder flow is of prime importance to manufacturers in ensuring high quality standards. Download this free...

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

Related suppliers